Medical/Pharmaceuticals
CentraLlVF Launches New Guaranteed Egg Donation Programs Through CEB and AWEB
Expanded blastocyst-guarantee programs now available through two CentraLlVF brands, supporting a wider range of Australian recipients LONDON, July 1, 2025 /PRNewswire/ -- CentraLlVF, a leading Australian provider of donor egg solutions, is proud to announce important program updates across both...
Wingderm USA Takes the Lead at TAS 2025, Cementing Its Local Presence in the U.S.
BEIJING, June 30, 2025 /PRNewswire/ -- Wingderm®, a leading innovator in energy-base medical aesthetic technologies, officially made its debut at The Aesthetic Show (TAS) 2025, held fromJune 27 to 29 in Las Vegas. This marks a key step as the brand grows in the U.S. medical aesthetic market. A...
AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
TOKYO, June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of up to $...
Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
* "The next decade will focus on securing strong growth momentum by strengthening product competitiveness and profitability" * First technology-special listed company to join the Corporate Value-Up Program… "We will grow by faithfully responding to stakeholder needs and expectations." YONGIN,...
Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...
Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals
TOKYO, June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration co...
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL * It reduces viscosity by up to 90% while maintaining formulation stability and injectability SHANGHAI, June 30, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), ...
Japanese Body Therapy (JBT) Launches Singapore-Based Expansion Hub, Targets 100 Centres Across Asia
SINGAPORE, June 30, 2025 /PRNewswire/ -- MJG INTERNATIONAL PTE. LTD. has formally launched Japanese Body Therapy (JBT) in Singapore, positioning the city-state as its operational base for regional growth. JBT is a structured body therapy brand offeringPM Balance Seitai—a traditional Japanese manu...
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO ) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A ...
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, Mass., June 30, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pf...
ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles
A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals that IVF cycles involving male partners over the age of 45 carry significantly increased miscarriage risks and lower live birth rates – even when youn...
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
LONDON, June 29, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology could pave the way for more effective...
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
SHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511).Under the t...
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies
SEOUL, South Korea, June 27, 2025 /PRNewswire/ -- As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal Spra...
Avio Health Launches World's First Functional Medicine LLM for Emagene Life, Transforming Personalized Healthcare
KUALA LUMPUR, Malaysia, June 27, 2025 /PRNewswire/ -- Avio Health, a deep-tech company dedicated to advancing healthcare through data analytics and machine learning, today announced the launch of the world's first Functional Medicine-based Large Language Model (LLM) developed exclusively for Ema...
TransThera Publishes Translational Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Annals of Oncology
NANJING, China and GAITHERSBURG, Md., June 27, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced that the translational studies of tinengotinib in CCA with acquired resistance to FGFR inhibitors were published inAnnals of Oncology (IF 56.7). Dr. Peng Peng, Vice President at T...
Yidu Tech's AI Agents Now Handle 20% of Hospital Tasks: Human-Machine Collaboration Model Showcased at Summer Davos
TIANJIN, China, June 27, 2025 /PRNewswire/ -- From June 24 to 26, the World Economic Forum 2025 Annual Meeting of the New Champions (the 16th Summer Davos Forum) was held inTianjin. Artificial intelligence, as the new frontier of global economic growth, was one of the hottest topics of this year'...
MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY
* In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will enhance biological and molecular understanding of various pathologies. MILAN, June 26, 2025 /PRNewswire/ -...
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 267 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 258 media titles]
2025-12-29 14:27